Vaccine

ClinicalJuly 4, 2026

Phase 1/2 Trial Shows Safety and Immunogenicity of COVID-19-Influenza Combination Vaccine

The COVID-19-Influenza Combination nanoparticle vaccine (CIC) demonstrated safety and immunogenicity comparable to standalone vaccines in a phase 1/2 trial.

Companies

Assets

Recent signals(11)

BEATRIX Study on Group B Streptococcus Vaccine in Pregnant Women Initiates Recruitment

BioNTech's mRNA Mpox Vaccine Candidate Enters Clinical Trial Phase

Post-marketing study shows cholera vaccine reduces diarrhea incidence in children

Vaxcyte Initiates Study on VAX-31 for Adults Over 50 with Prior Pneumococcal Vaccination

Phase 1/2 Trial Shows Safety and Immunogenicity of COVID-19-Influenza Combination Vaccine

Phase 3 Trial of ROTAVAC 5D Vaccine in Chilean Infants Underway

Moderna initiates safety and immunogenicity study for RSV vaccines in infants

Challenges in Rotavirus Vaccine Efficacy in Low- and Middle-Income Countries

New Non-Aqueous Rotavirus Vaccine Shows Promise for Ambient Shipping and Stability

mRNA-1083 Shows Durable Immune Response and Safety in Adults ≥50 Years

Nanomaterial-based vaccines show promise for improved rotavirus protection

Upcoming catalysts

Indications

Get signals before the market moves